Skip to main contentSkip to navigation
Sirius Investors
Roivant Sciences Ltd.

Roivant Sciences Ltd.

ROIV
NASDAQHealthcare

Roivant Sciences Ltd. (ROIV) Investment Research Dashboard

About Roivant Sciences Ltd. (ROIV) stock analysis

Get live ROIV stock price $34.72, comprehensive Roivant Sciences Ltd. stock analysis, charts, news, sentiment, sector analysis, and expert forecast. Real-time ROIV stock data and investment insights.

34.72
0.83%Today
Market Cap
24.97B
Volume
3.95M
52W High
37.00
52W Low
10.90

Loading chart data...

Investment Score

TTM (current)
Unavailable

A systematic tri-factor framework (valuation, quality, momentum) using trailing twelve-month fundamentals and current price momentum—aligned with the full investment score dashboard.

Score unavailable for this asset.

0-39

Defensive posture

40-54

Mixed / wait for confirmation

55-69

Constructive setup

70-100

Attractive zone

Total Score

Value

Cheapness vs fundamentals and cash generation

Quality

Durability of profitability and balance sheet

Momentum

Price trend strength and persistence

Professional usage: treat the score as a ranking and risk-filtering tool, then confirm with earnings revision trend, competitive positioning, and valuation relative to peers before capital allocation.

Company Overview

Roivant Sciences Ltd. is a biopharmaceutical and healthcare technology company dedicated to discovering and advancing innovative therapeutic drugs. The firm's development pipeline targets a broad spectrum of diseases, including various forms of solid...

Company Information

CEO
Matthew Gline
Sector
Healthcare
Industry
Biotechnology
Employees
721

Contact Information

Address
11-12 St. James's Square
Country
GB

Investment Analysis & Business Insights

Healthcare
Biotechnology

Investment Highlights

Strong presence in the Healthcare sector with established market position

Important Investment Considerations

  • All investments carry risk, including potential loss of principal for Roivant Sciences Ltd. shareholders
  • Market volatility can significantly impact stock price, especially for mid-cap stocks
  • Sector-specific risks in Healthcare may affect company performance
  • Past performance does not guarantee future results for Roivant Sciences Ltd.
  • Investors should consider how Roivant Sciences Ltd. fits within their overall portfolio allocation
  • Valuation metrics suggest potential, but require fundamental analysis

Market Cap

24.97B

P/E Ratio (TTM)

-35.69

Beta

1.11

Data Sources & Methodology

Financial data on this page is sourced from verified SEC EDGAR filings (10-K, 10-Q, 8-K reports), real-time market data providers, and official company disclosures. All analysis is generated using AI models trained exclusively on reliable financial documents. For detailed information about our data sources and methodology, see our Methodology page.Not investment advice.

About Healthcare Sector

The Healthcare sector includes companies that provide medical services, develop pharmaceuticals, manufacture medical devices, and offer health insurance.

Healthcare (1D)

72/100 ⭐⭐⭐⭐⭐

Overall
-0.1%
NYSE
-0.1%
NASDAQ
-0.1%
Sector1D1W1MP/EScore
Consumer Defensive+1.3%+3.3%+2.2%29.2
88/100⭐⭐⭐⭐⭐
Financial Services-0.1%+0.9%+2.0%19.3
86/100⭐⭐⭐⭐⭐
Communication Services+0.4%-1.6%+2.0%22.2
74/100⭐⭐⭐⭐⭐
Healthcare-0.1%+0.5%+0.8%23.5
72/100⭐⭐⭐⭐⭐
Basic Materials-0.7%+0.1%-1.3%24.9
60/100⭐⭐⭐⭐
Energy-0.4%-2.0%-2.4%19.4
51/100⭐⭐⭐
Utilities-1.5%-0.5%-4.9%25.4
40/100⭐⭐⭐
Real Estate-1.6%-1.1%-3.5%29.4
36/100⭐⭐
Industrials-0.4%-0.5%-10.7%30.5
19/100
Consumer Cyclical-0.3%-2.3%-6.5%43.1
17/100
Technology-1.9%-4.0%-9.4%41.9
7/100

Sector returns combine NYSE and NASDAQ averages. P/E is the latest blended sector multiple. Sector score ranks each sector vs peers using percentile ranks (not fixed thresholds): 48% 1M + 24% 1W + 8% 1D + 20% P/E (lower P/E ranks higher). Data as of 2026-07-28.